SRNE Stock Recent News
SRNE LATEST HEADLINES
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
These two penny stocks could generate life-changing gains for early shareholders.
A positive clinical readout in lung cancer is fueling the biotech's rally today.
Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.
The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic function. The Phase 1 study will examine the PK in patients with moderate renal and.
Sorrento's outsized ambitions are not playing well for shareholders. Sorrento has assembled a significant group of COVID-19 assets that could perk up its value as the pandemic smolders ever hotter.
Healthcare has become a bona fide stock picker's market this year.
Are these penny stocks worth buying right now? The post Hot Penny Stocks to Buy This Week?
The biotech's bargain-basement valuation appears to be attracting investors' interest.
Penny stocks to watch right now The post Best Penny Stocks To Watch? 4 For Your Independence Day List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.